Elsevier

Journal of Hepatology

Volume 48, Issue 4, April 2008, Pages 548-558
Journal of Hepatology

Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment

https://doi.org/10.1016/j.jhep.2007.12.014Get rights and content

Background/Aims

HCV-specific T cells in acute hepatitis C with subsequent chronic evolution are dysfunctional and most of them express PD-1. The aim of the study was to investigate to what extent the antiviral T cell function can be restored by reversing T cell exhaustion by PD-1/PD-L1 blockade and to assess whether this restoration is favored by IFN-α treatment.

Methods

PD-1 and PD-L1 expression was studied on T cells and dendritic cells, respectively, of 14 patients with acute hepatitis C and different evolutions of infection. The effect of anti-PD-L1 was analyzed on proliferation, cytokine production and cytolytic activity of CD4 and CD8 T cells.

Results

While PD-1 expression dropped concurrently with spontaneous or IFN-α induced HCV–RNA decline, PD-L1 levels on dendritic cells increased during IFN-α treatment. Anti-PD-L1 antibodies improved expansion and cytokine production but not the cytolytic activity of HCV-specific T cells. This restoration tended to be greater at lower levels of viremia and PD-1 expression and during PEG-IFNα treatment.

Conclusions

PD-1/PD-L1 blockade has an immunoregulatory activity which may synergize with the antiviral effect of IFN-α therapy and should be thus explored further in long-lasting chronic HCV infections in the perspective of improving the efficacy of available antiviral treatments.

Introduction

The hepatitis C virus (HCV) establishes persistent infection and causes chronic liver injury in the majority of infected individuals. The adaptive immunity has a central role in the pathogenesis of this viral infection and understanding the behavior of the T cell response is crucial for the design of effective strategies to control HCV [1], [2], [3], [4], [5]. Different studies in the chronic as well as in the early acute phase of HCV infection have suggested that a functional impairment of the HCV-specific cell-mediated immune response plays an important role in HCV persistence [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17]. Moreover, recent studies have provided us with a better understanding of both the positive and negative signals regulating the antigen-specific T cell function and their importance with respect to the outcome of viral infections [18], [19], [20]. PD-1/PD-L1 molecules are part of one of these regulatory pathways that has first been reported to inhibit the virus-specific CD8 cell function in lymphocytic choriomeningitis virus infection [21], [22]. PD-1 is expressed on thymocytes and it is up-regulated on activated T and B cells [21], [22]. Its ligands are the PD-L1 and PD-L2 molecules; PD-L2 expression is limited to professional antigen-presenting cells (APCs), whereas PD-L1 has a much broader tissue distribution and it has recently been described to be induced in hepatocytes by viral infection and by interferon-alpha and -gamma [21], [22], [23]. PD-1 engagement blocks cellular entry into the cell cycle and the production of effector cytokines [21], [22]. Many recent findings indicate that this pathway plays a role also in the pathogenesis of human infections caused by HBV, HIV and HCV [24], [25], [26], [27], [28], [29], [30], [31], [32]. Previous studies performed both in acute and in chronic HCV infection indicated that PD-1 is highly expressed by HCV-specific CD8 cells and that blockade of the PD-1/PD-L1 pathway by anti-PDL-1 antibodies can improve the function of HCV-specific CD8 cells [7], [29].

In continuation of these studies, the present work was undertaken to better understand to what extent the antiviral function of CD4 and CD8 cells can be reconstituted by PD-1/PD-L1 blockade in situations of chronic exposure to high viral antigen concentrations and whether antiviral therapy in chronically evolving acute HCV infections can facilitate this immunological reconstitution. Our data suggest that increasing amounts of virus in patients with chronic evolution of HCV infection are associated with enhanced expression of PD-1 on virus-specific CD8 cells and a lower likelihood of functional T cell restoration by PD-1/PD-L1 blockade. A better recovery of the T cell function was observed at lower levels of viremia and under IFN-α/ribavirin therapy. Although limited to a small cohort of patients, this more efficient effect of anti-PD-L1 observed under antiviral therapy suggests a possible strategy to improve the efficacy of IFN/ribavirin treatment to be assessed in patients with a long-lasting condition of chronic HCV infection who require improved protocols of therapy to increase their sustained response rate.

Section snippets

Patients

A total of 14 patients were enrolled at the Unit of Infectious Diseases and Hepatology of the Azienda Ospedaliero-Universitaria and were studied from the acute phase of HCV infection to one–two years of follow-up. All patients were infected by HCV genotype 1. Six of them with persistent elevation of serum alanine aminotransferase (ALT) levels and persistently positive HCV–RNA were treated with IFN-α plus ribavirin 3 to 6 months after the onset of acute hepatitis. The diagnosis of acute

PD1 and PDL-1 expression is related to viremia levels and IFN-α treatment

PD-1 MFI was analyzed on virus-specific CD8 cells of 12 HLA-A2 positive patients using tetramers containing three different HLA-A2 restricted HCV epitopes (NS3 1073, NS3 1406, NS4 1992). By plotting PD-1 MFI values against the corresponding viremia levels derived from all time points tested in each patient, a linear correlation was found between PD-1 mean fluorescence intensity (MFI) and HCV–RNA (p < 0.001) (Fig. 1A). The decline of viremia, either spontaneous of induced by IFN-α therapy, was

Discussion

It is well known that HCV has a high propensity to persist. To accomplish this, the virus has developed several strategies to evade HCV-specific T cell responses [3], [4]. These include the direct inhibitory effect of viral proteins on T cell responses and the emergence of escape mutations [33], [34], [35]. Moreover, viral proteins can interfere with viral recognition by the innate immune system, thereby making innate responses poorly efficient in the early containment of infection [36].

References (44)

  • S.F. Wieland et al.

    Stealth and cunning: hepatitis B and hepatitis C viruses

    J Virol

    (2005)
  • D.E. Kaplan et al.

    Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C

    Gastroenterology

    (2007)
  • A. Penna et al.

    Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection

    Hepatology

    (2007)
  • S. Urbani et al.

    The outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses

    Hepatology

    (2006)
  • A.L. Cox et al.

    Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C

    Hepatology

    (2005)
  • R. Thimme et al.

    Determinants of viral clearance and persistence during acute hepatitis C virus infection

    J Exp Med

    (2001)
  • N.H. Shoukry et al.

    Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection

    J Exp Med

    (2005)
  • S. Urbani et al.

    Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C

    J Virol

    (2004)
  • H. Wedemeyer et al.

    Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection

    J Immunol

    (2002)
  • N.H. Gruener et al.

    Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus

    J Virol

    (2001)
  • F. Lechner et al.

    Analysis of successful immune responses in persons infected with hepatitis C virus

    J Exp Med

    (2000)
  • D.K. Wong et al.

    Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection

    J Immunol

    (1998)
  • Cited by (0)

    The authors declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

    View full text